This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Mark Emalfarb
Chief Executive Officer at Dyadic International Inc


Mark A. Emalfarb is the founder and CEO of Dyadic International, Inc., which celebrated its 41st anniversary in January 2020. Dyadic is a Nasdaq listed (DYAI) global biotechnology company with operations in the US & EU. He is the inventor of more than 25 U.S. and foreign biotechnology patents and patent applications.  
Mr. Emalfarb has led Dyadic through a variety of evolutionary changes, including its recent transition from an industrial biotech company, with the sale of its industrial biotechnology business to DuPont for $75 million in cash. This repositioned Dyadic into the biopharmaceutical industry, where the company is leveraging its industrially proven, patented and proprietary C1 gene expression platform to help enable and speed the development lower the cost of biologic and improve the performance of biologic vaccines and drugs.
Since the DuPont transaction, Dyadic has entered into more than a dozen research collaborations with big pharma, biotech, academic and government organizations such as the US Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates which will be utilized by the Vaccine Research Center (VRC) part of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health. EU Zoonosis Anticipation Preparedness Initiative (ZAPI), The Israel Institute for Biological Research (IIBR), Sanofi-Aventis, The Serum Institute of India, Syngene a subsidiary of Biocon (India), Medytox (Korea), WuXi Biologics (China), Jiangsu Hengrui Medicine (China) and several others.  
Mr. Emalfarb was a member of the University of Iowa Hawkeye NCAA Championship Wrestling Teams.

Agenda Sessions

  • A TRANSFORMATIONAL PLATFORM THAT TRANSCENDS THE LIMITS OF LEGACY PROTEIN PRODUCTION TECHNOLOGIES-Dyadic Thermophilic Filamentous Fungus (C1 platform) Recombinant Production of Glycoprotein Antigen Vaccines, Antibodies & Other TherapeuticProtein Product - Mark Emalfarb, Dyadic International Inc, CEO"